-
My Account
In App
My Account
BSE Live
Oct 29, 12:02Prev. Close
1290.50
Open Price
1296.40
Bid Price (Qty.)
1290.25 (14)
Offer Price (Qty.)
1291.00 (5)
NSE Live
Oct 29, 12:02Prev. Close
1289.40
Open Price
1299.00
Bid Price (Qty.)
1291.00 (11)
Offer Price (Qty.)
1291.10 (35)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | |
| Total Share Capital | 83.40 | 83.40 | 83.30 | 83.20 | 83.20 | |
| Reserves and Surplus | 28,773.20 | 24,157.40 | 20,390.90 | 18,253.00 | 16,900.50 | |
| Total Reserves and Surplus | 28,773.20 | 24,157.40 | 20,390.90 | 18,253.00 | 16,900.50 | |
| Total Shareholders Funds | 28,856.60 | 24,240.80 | 20,474.20 | 18,336.20 | 16,983.70 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 515.40 | 416.10 | 339.20 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 261.70 | 155.00 | 113.80 | 103.90 | 60.50 | |
| Long Term Provisions | 5.40 | 9.30 | 7.90 | 10.40 | 25.10 | |
| Total Non-Current Liabilities | 782.50 | 580.40 | 460.90 | 114.30 | 85.60 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 3,385.50 | 710.00 | 0.60 | 2,171.10 | 1,180.90 | |
| Trade Payables | 1,993.10 | 2,044.80 | 1,764.50 | 1,666.20 | 1,336.40 | |
| Other Current Liabilities | 2,933.70 | 2,455.00 | 2,369.40 | 1,885.60 | 1,744.30 | |
| Short Term Provisions | 339.50 | 328.30 | 305.20 | 322.20 | 298.70 | |
| Total Current Liabilities | 8,651.80 | 5,538.10 | 4,439.70 | 6,045.10 | 4,560.30 | |
| Total Capital And Liabilities | 38,290.90 | 30,359.30 | 25,374.80 | 24,495.60 | 21,629.60 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 5,865.40 | 5,109.40 | 4,737.90 | 4,024.00 | 3,579.20 | |
| Intangible Assets | 2,367.00 | 2,479.70 | 2,468.80 | 2,126.50 | 2,265.10 | |
| Capital Work-In-Progress | 2,156.40 | 1,171.90 | 899.10 | 1,186.40 | 877.10 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 10,429.20 | 8,800.10 | 8,119.70 | 7,350.80 | 6,745.10 | |
| Non-Current Investments | 10,310.50 | 3,202.70 | 3,142.20 | 3,024.30 | 3,392.20 | |
| Deferred Tax Assets [Net] | 124.40 | 316.10 | 254.60 | 19.40 | 254.80 | |
| Long Term Loans And Advances | 1.40 | 61.70 | 1.10 | 1.20 | 1.20 | |
| Other Non-Current Assets | 922.40 | 162.80 | 68.90 | 616.30 | 292.10 | |
| Total Non-Current Assets | 21,787.90 | 12,543.40 | 11,586.50 | 11,012.00 | 10,685.40 | |
| CURRENT ASSETS | ||||||
| Current Investments | 2,883.00 | 4,117.90 | 4,297.80 | 1,912.40 | 1,257.00 | |
| Inventories | 4,575.80 | 4,018.90 | 3,043.00 | 3,347.80 | 2,819.70 | |
| Trade Receivables | 5,959.00 | 4,623.90 | 4,288.90 | 4,945.40 | 4,080.00 | |
| Cash And Cash Equivalents | 976.80 | 1,216.90 | 645.80 | 2,030.50 | 1,646.50 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| OtherCurrentAssets | 2,108.40 | 3,838.30 | 1,512.80 | 1,247.50 | 1,141.00 | |
| Total Current Assets | 16,503.00 | 17,815.90 | 13,788.30 | 13,483.60 | 10,944.20 | |
| Total Assets | 38,290.90 | 30,359.30 | 25,374.80 | 24,495.60 | 21,629.60 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,432.61 | 1,763.60 | 830.20 | 827.40 | 1,062.80 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 5,555.40 | 4,534.80 | 4,148.40 | 4,040.10 | 3,442.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | 15,939.50 | 14,670.20 | 12,880.30 | 10,154.40 | 9,769.90 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 55.87 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | -- | -- | -- | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
27.10.2025
Hold Dr Reddys Laboratories: target of Rs 1250: ICICI Securities
27.10.2025
Reduce Dr Reddys Laboratories; target of Rs 1270: Prabhudas Lilladher
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz
